384 related articles for article (PubMed ID: 31374367)
1. Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy.
McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Friedlander M; Bosco A; Harrison M; Maier N; O'Neill S; Park SB
J Pain Symptom Manage; 2019 Dec; 58(6):1023-1032. PubMed ID: 31374367
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
[TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
[TBL] [Abstract][Full Text] [Related]
4. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
6. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
[TBL] [Abstract][Full Text] [Related]
7. Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey.
McCrary JM; Goldstein D; Boyle F; Cox K; Grimison P; Kiernan MC; Krishnan AV; Lewis CR; Webber K; Baron-Hay S; Horvath L; Park SB;
Support Care Cancer; 2017 Nov; 25(11):3485-3493. PubMed ID: 28589310
[TBL] [Abstract][Full Text] [Related]
8. Validity of the chemotherapy-induced peripheral neuropathy self-check sheet.
Miyoshi Y; Onishi C; Fujie M; Senoo N; Wakatsuki R; Suzumiya J
Intern Med; 2015; 54(7):737-42. PubMed ID: 25832934
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study.
Chen CS; Kim J; Garg N; Guntupalli H; Jagsi R; Griggs JJ; Sabel M; Dorsch MP; Callaghan BC; Hertz DL
JMIR Mhealth Uhealth; 2021 Jul; 9(7):e27502. PubMed ID: 36260403
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
[TBL] [Abstract][Full Text] [Related]
11. Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time.
Wang M; Cheng HL; Lopez V; Sundar R; Yorke J; Molassiotis A
BMC Cancer; 2019 Nov; 19(1):1151. PubMed ID: 31775665
[TBL] [Abstract][Full Text] [Related]
12. Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy.
Knoerl R; Gray E; Stricker C; Mitchell SA; Kippe K; Smith G; Dudley WN; Lavoie Smith EM
Support Care Cancer; 2017 Nov; 25(11):3437-3446. PubMed ID: 28577231
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
Nyrop KA; Deal AM; Reeder-Hayes KE; Shachar SS; Reeve BB; Basch E; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB
Cancer; 2019 Sep; 125(17):2945-2954. PubMed ID: 31090930
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of the comprehensive assessment scale for chemotherapy-induced peripheral neuropathy in survivors of cancer.
Kanda K; Fujimoto K; Mochizuki R; Ishida K; Lee B
BMC Cancer; 2019 Sep; 19(1):904. PubMed ID: 31506070
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-Induced Peripheral Neuropathy Assessment Tools: A Systematic Review.
Haryani H; Fetzer SJ; Wu CL; Hsu YY
Oncol Nurs Forum; 2017 May; 44(3):E111-E123. PubMed ID: 28635977
[TBL] [Abstract][Full Text] [Related]
16. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).
Binda D; Vanhoutte EK; Cavaletti G; Cornblath DR; Postma TJ; Frigeni B; Alberti P; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Rossi E; Valsecchi MG; Faber CG; Merkies IS; ; Galimberti S; Lanzani F; Mattavelli L; Piatti ML; Bidoli P; Cazzaniga M; Cortinovis D; Lucchetta M; Campagnolo M; Bakkers M; Brouwer B; Boogerd W; Grant R; Reni L; Piras B; Pessino A; Padua L; Granata G; Leandri M; Ghignotti I; Plasmati R; Pastorelli F; Heimans JJ; Eurelings M; Meijer RJ; Grisold W; Lindeck Pozza E; Mazzeo A; Toscano A; Russo M; Tomasello C; Altavilla G; Penas Prado M; Dominguez Gonzalez C; Dorsey SG
Eur J Cancer; 2013 Sep; 49(13):2910-8. PubMed ID: 23668917
[TBL] [Abstract][Full Text] [Related]
17. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
Kuriyama A; Endo K
Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
[TBL] [Abstract][Full Text] [Related]
19. Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity.
Park SB; Alberti P; Kolb NA; Gewandter JS; Schenone A; Argyriou AA
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S13-S25. PubMed ID: 31647154
[TBL] [Abstract][Full Text] [Related]
20. Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study.
Parsons SK; Rodday AM; Pei Q; Keller FG; Wu Y; Henderson TO; Cella D; Kelly KM; Castellino SM
J Patient Rep Outcomes; 2023 Nov; 7(1):113. PubMed ID: 37947987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
